6/28/23, 11:02 PM LoDoCo Pathway Feedback Search Clinical Topics Home Studies LoDoCo LoDoCo Disease Coronary artery disease Trial question What is the role of low-dose colchicine in patients with clinically stable coronary disease? Study design Multi-center Open label RCT Population Characteristics of study participants 11.0% female N = 532 89.0% male 532 patients (59 female, 473 male) Inclusion criteria: patients with stable coronary disease receiving aspirin and/or clopidogrel and statins Key exclusion criteria: contraindication to colchicine, history of bypass surgery < 10 years ago, unwilling to provide consent, or major competing comorbidities Interventions N=282 colchicine (0.5 mg/day) N=250 control (no colchicine) Primary outcome Acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke https://web.pathway.md/studies/recorBqAmzbNrTOwN 1/2 6/28/23, 11:02 PM LoDoCo Pathway 16.0 % 16 12.0 % 8.0 % Significant decrease 5.3 4.0 % NNT = 9 0.0 % Colchicine Control Significant decrease in acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke (5.3% vs. 16%; HR 0.33, 95% CI 0.18 to 0.59) Secondary outcomes Significant decrease in acute coronary syndrome (4.6% vs. 13.6%; HR 0.33, 95% CI 0.18 to 0.63) Significant decrease in Acute coronary syndrome nonstent-related (3.2% vs. 12%; HR 0.26, 95% CI 0.12 to 0.55) Significant decrease in nonstent-related acute myocardial infarction (1.6% vs. 5.6%; HR 0.25, 95% CI 0.08 to 0.76) Conclusion In patients with stable coronary disease receiving aspirin and/or clopidogrel and statins, colchicine was superior to control with respect to acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke. Reference Nidorf SM, Eikelboom JW, Budgeon CA et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 Jan 29;61(4):404-410. Open reference URL https://web.pathway.md/studies/recorBqAmzbNrTOwN 2/2